Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018

Summary

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-β2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth.

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Proliferative Vitreoretinopathy (PVR) and Scar.

The latest report Transforming Growth Factor Beta 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope

- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)

- The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most...
attractive projects to enhance and expand business potential and scope

Additional Details

Publisher: Global Markets Direct
Reference: GMDHC1426TDB
Number of Pages: 50
Report Format: PDF
Publisher Information:
Table Of Contents for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018 [Report Updated: 24-04-2018]

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Overview
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Companies Involved in Therapeutics Development
- Genzyme Corp
- Isarna Therapeutics GmbH
- Novartis AG
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Drug Profiles
- decorin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fresolimumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ISTH-0036 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ISTH-0047 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- OT-201 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- trabedersen - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- XOMA-089 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Dormant Products
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Discontinued Products
- Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Product Development Milestones
- Featured News & Press Releases
- May 15, 2017: Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference
- Sep 02, 2016: Oncotelic and Autotelic Announce Clinical Data Supporting IL-8 Spike as a Prognostic Biomarker for Immunotherapy
- May 04, 2016: Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference
- Mar 09, 2016: Results Of A Phase I/II Trial Of Ot-101 In Advanced Melanoma Patients
- Mar 01, 2016: Oncotelic Presents Treatment With Trabedersen- AN ANTI-TGF-BETA-2 ANTISENSE- Primed Tumors To Subsequent Chemotherapies
- Feb 29, 2016: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen
- Jun 10, 2015: FDA Awards Isarna Orphan Drug Designation for ISTH0036 to Improve Glaucoma Treatment Outcome
- May 21, 2015: Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma
- May 11, 2015: Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma
- Apr 16, 2015: Isarna Initiates First-in-Human Phase I Trial for ISTH0036 to Treat Advanced Glaucoma
- Nov 04, 2014: Oncodesign announces the third extension of a research contract with Isarna Therapeutics
- Feb 26, 2013: Antisense Pharma Provides Update On Clinical Development Program Of Trabedersen
- Jul 24, 2012: Antisense Pharma Receives FDA Orphan Drug Designation For Trabedersen To Treat Malignant Melanoma
- Jun 04, 2012: Antisense Pharma Presents Trabedersen Phase I/II Complete Data At ASCO Annual Meeting
- Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen

© BioPortfolio Limited - 2019
https://www.bioportfolio.co.uk/product/209754
reportstore@bioportfolio.com to order
How to Buy...

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018 [Report Updated: 24-04-2018]

**Option 1 - Online**
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/209754

**Option 2 - Request a Proforma Invoice**
Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

- Your Name:
- Job Title:
- Your Email:
- Your Contact Phone:
- Company Name:
- Address:
- Post/Zip Code:
- Country:
- P.O. Number:
- Any Other Instructions:

**Pricing Options:** (please tick one)
- $3500 | Single User Price
- $7000 | Site License Price
- $10500 | Enterprise License Price

**Payment Options:** (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

**Authorising Signature:**

**Option 3 - Phone Us on +44 (0)1300 321501**
We will be delighted to give you our personal attention.